Spectral Diagnostics Inc. (SDI) posted third-quarter sales of $815,000 for the three months ended Sept. 30, up 16.3 percent compared with $701,000 during the same period last year. Losses widened 29.2 percent to $429,000, compared with $332,000 million during Q3 2008:
Press Release
Spectral announces third quarter 2009 results
“During the quarter, the Company’s primary focus was on the U.S. regulatory strategy and commercialization of Toraymyxin(TM) as an effective treatment for severe sepsis. We completed the protocol design for a clinical trial and we are evaluating a number of strategic and financial options that would allow us to start the trial in the first half of 2010,” said Dr.
Financial Review
For the third quarter ended
Operating expenses for the third quarter ended
For the third quarter ended
Cash and short term investments as at
About Spectral Diagnostics
Spectral is a leader in the battle against sepsis. Spectral’s lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed to treat endotoxemia, Spectral is well-positioned to promote the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. Spectral is listed on TSX under the symbol SDI.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.